The cAMP cascade is an intracellular signal transduction system thought to be important for neuronal regulation and information storage. cAMP production is reduced in platelets from patients with fragile X syndrome. In the present study we assayed cAMP metabolism, Xq27.3 fragile site percentages, size of amplification mutation in fragile X mental retardation-1 gene (FMR-1), and FMR-1 mRNA levels in 21 lymphoblastoid cell lines (LCL) from fragile X patients. cAMP production was diminished in fragile X LCL relative to controls (n = 20) when cells were assayed in prostaglandin E 1 (74%, P < 0.02) and in forskolin (64%, p < 0.1) although the difference was statistically significant only in prostaglandin E 1 . The length of the FMR-1 amplification mutation correlated with measures of cAMP production which were unassociated with receptor activation (r = -0.53, p = 0.02, and r = -0.48, P = 0.03, for unstimulated and forskolin-stimulated cAMP production, respectively). In fragile site percentages did not correlate with any cAMP production. All fragile X LCL showed abThe cAMP cascade is a second messenger cascade which is thought to regulate neuronal functions and produce short-term sensitization (or neuronal memory) through the following mechanism (for reviews, see Refs. 1 and 2). Cell membrane receptors bind neurotransmitters or other neuroactive ligands causing interaction of receptor proteins with signal-transducing OTP-binding regulatory subunits (G, or 0i for stimulatory or inhibitory, respectively) of adenylate cyclase. Regulatory subunits then interact with a catalytic subunit of adenylate cyclase to increase or decrease production of cAMP. Intracellular cAMP binds to regulatory subunits of cAMP-dependent protein kinases and activates these kinases resulting in phosphorylation and activation (or deactivation) of their protein or enzyme substrates and, thus, modification of neuronal synaptic
The cAMP cascade is an intracellular signal transduction system thought to be important for neuronal regulation and information storage. cAMP production is reduced in platelets from patients with fragile X syndrome. In the present study we assayed cAMP metabolism, Xq27.3 fragile site percentages, size of amplification mutation in fragile X mental retardation-1 gene (FMR-1), and FMR-1 mRNA levels in 21 lymphoblastoid cell lines (LCL) from fragile X patients. cAMP production was diminished in fragile X LCL relative to controls (n = 20) when cells were assayed in prostaglandin E 1 (74%, P < 0.02) and in forskolin (64%, p < 0.1) although the difference was statistically significant only in prostaglandin E 1 . The length of the FMR-1 amplification mutation correlated with measures of cAMP production which were unassociated with receptor activation (r = -0.53, p = 0.02, and r = -0.48, P = 0.03, for unstimulated and forskolin-stimulated cAMP production, respectively). In fragile site percentages did not correlate with any cAMP production. All fragile X LCL showed abThe cAMP cascade is a second messenger cascade which is thought to regulate neuronal functions and produce short-term sensitization (or neuronal memory) through the following mechanism (for reviews, see Refs. 1 and 2). Cell membrane receptors bind neurotransmitters or other neuroactive ligands causing interaction of receptor proteins with signal-transducing OTP-binding regulatory subunits (G, or 0i for stimulatory or inhibitory, respectively) of adenylate cyclase. Regulatory subunits then interact with a catalytic subunit of adenylate cyclase to increase or decrease production of cAMP. Intracellular cAMP binds to regulatory subunits of cAMP-dependent protein kinases and activates these kinases resulting in phosphorylation and activation (or deactivation) of their protein or enzyme substrates and, thus, modification of neuronal synaptic properties. Phosphodiesterases hydrolyze cAMP and phosphatases dephosphorylate protein substrates.
The cAMP cascade can produce long-term changes in neuronal responsiveness (3), presumably via induction of phosphorylation of transcription factors which bind AP-2 or CRE consensus sites in the promoters of specific genes, thereby enhancing or inhibiting transcription of selective groups of genes. This process is thought to play a role in long-term sensitization in simple organisms and learning in higher organisms (4).
Biochemical lesions affecting regulation or activity of this cascade in lower organisms and humans, as expected, produce learning or memory deficits. In Aplysia, blockade of cAMP synthesis or injection of inhibitors of PK-A prevents short-term sensitization of the gill withdrawal reflex and longer-term changes in protein synthesis (5) . Learning-deficient Drosophila mutants (6) have decreased activity of various cAMP cascade proteins including phosphodiesterase (dunce), catalytic subunit of adenyl ate cyclase (rutabaga), neurotransmitter production (Ddc), and G, regulatory subunit (turnip). In humans, patients cAMP IN FRAGILE X SYNDROME 639 with type la pseudohypop arath yroidism and myotonic dystrophy have learning deficiency and diminished activit y and genetic lesions of the G s regulatory subunit of aden ylate cyclase (7) and a cAMP-dependent protein kinase (8) , respectively. Previous studies fro m our laboratory have demonstrat ed diminished cA MP production in plat elets from patients with fragile X syndrome relative to normal controls and patients with non specific mental retardation or autistic disorder (9, 10) .
Fragile X syndrome is an X-linked ment al retardation sy ndrome associated with a folate-sensitive fragile site at band Xq 27.3. It is the most common inherited mental retard ation sy ndrome, with an incidence of 1:1250 for male s (11) . In addition to mental retard ation, patients with fragil e X sy ndrome manifest variable facial dysmorphism, large ears, long narrow face, and testicular enlargement. The fragile site serves mainl y as a marker for the presence of a large fragil e X mut ation (full mut ation), wh ich is now known to consist of an amplification of a var iable siz e unstable trinucleotide repeat sequence (CG G) pre sent in the first exo n of the fragil e X gene, FMR-1 (12) . Sm all amplifications « 200 repea ts) of this sequence (premutation) do not produce fragil e X sy ndro me but are unstable and may ex pand to the full mutation wh en passed by a fem ale to her offspring (13) . Lar ge amplifications (> 300 repeats) of this sequence result in hypermethylation of the FMR-1 prom oter region (14) , inactivation of the gene, loss of expression of the FMR-1 mRNA (15) and protein (16) , and henc e, the clinical syndrome. Because of the instability of the amplified sequence, mosaicism for size and/or meth ylation status of the mut ation is common in fragil e X patients (15) , and some pati ents with borderlin e mutation size (200 -300 repeats) exhibit only partial methylation and tend to be " higher functioning" (17) . Although absence of the FMR-1 protein appears to produce cogn itive dysfun ction, its role in neur al function and/or development is not known. In this study, LCL were used to examine cAMP production in a second fragile X tissue and to explore relationships betw een cAMP production and cytogenetic and molecular findings in fragil e X cells in a stand ardized setting free of dietary or drug effects.
METHODS

Patients.
Patients with frag ile X synd rom e we re recruite d from the Fragi le X Clinic at RUSH-Presbyterian-St. Luk e' s Medical Ce nter or from the Fragile X Association of Am erica. All patients in the fragil e X group were affected male s (age range 4-50, n = 21) with a clinical phen otyp e consistent with the syndrome . Mental disabilit y, as expected, was quite var iable with ment al retardation in 20 patients (4 severe, 11 moderate, S mild) and 1 patient with an IQ in the normal range. All patient s had multiple be havioral traits associated with fragile X sy ndrome; all had attentional difficultie s and so me degree of hyperactivity. Th e majority also had a high level of anxiety, eye avers ion, and perseverative speech. Sixt een patients manifested typical facial dysmorphism with large or prominent ears, long face, and midfacial hypoplasia. Th e remaining five manifested some to none of these features. Confirmation of the diagn osis in each pati ent was made by cytoge netic tes ting demonstrating a significant percentage (> 10%) of folate-se nsitive fragil e sites at Xq27 .3 or by direct DNA analysis of FMR-1 demonstrating a full mut ation. Controls wer e unmedicated, normally intell igent male and fe male subjects (age range 6-60 y).
Cell culture and cA MP measurement. Blood (10 mL in heparinized tubes) was obtained from fragile X patients or controls. Lymphocytes were isol ated on Ficoll -Paqu e (Pharmacia, Piscataway, NJ) gradients, transform ed wit h EBV , and grown in RPMI 1640 (Life Te chn ologies, Inc ., Ga thersburg, MD ) containing 10% FCS. Cell s were passaged 6 d before assay and fed 2 d before assay. Th ey were 80 -90% confluent at the time of assay. Tripli cate tub es containing lymphobl astoid cell suspensions were incubated with appropriate drug s for 30 min at 35°C. IBMX (1 mM) was used to inhibit phosphodiesterase, PGE 1 (10 fLM ) to measure rec eptor-dependent stimulation of cA MP production, and FSK (50 fLM ) to directl y activa te the catalytic subunit of adenylate cyclase. Although several age nts (PGE 1 , isoproterenol, and chloroadenosin e) stimulated cA MP production in LCL via a rec eptor-mediated mech anism, PGE 1 was chose n for use in LCL studies becau se it was the most potent cA MP stimulator and for continuity with studies of PGE1-stimulated cAMP production in platelets from fragile X patients. cAMP was extracted as described elsewhere (9) . Protein was me asured by the method of Lowry et al. (18) and cA MP by RIA (19) .
During early experiments designed to characterize cA MP responsiveness of LCL, several lines we re assayed two to three times, and some interassay variability in the mag nitude of cAMP production values measured was noted , with as much as 2-3-fold differences in measur ements for the same line in different assays. Th e relative cAMP produ ction between lines, however, was genera lly constant between assa ys (lines with high est cAMP levels were alwa ys highe st despite changes in the magnitude of the values). To minimize effects of interassay variability on the result s of this study, 8-11 LCL were includ ed in each cAMP assay, with roughly even numb ers of fragil e X and control LCL in each assay . Each line was assayed once (in triplicate) for this study. Molecul ar and cA MP studies we re perform ed on LCL of identi cal ea rly passage and cytogenetic studies were completed wi thin several passages.
Cytogenetic analysis. LCL were dilut ed in M1 99 (Life Techn ologies, Inc. ) w ith 5% FCS 48 h before harvest, and 0.1 fLM fiuorode oxyur idine was add ed 24 h before harvest. Colcemid (1 fLg/lO mL) was added for the final hour of culture, and cells were pelleted, fixed, and subj ected to routine cytogenetic analysis. Fragil e site percentages were calculated based on 50-100 cells exa mined.
Southern blot and PCR analysis of FMR-l. Direct DNA
analys is of the fragile X amplification mutation within FMR-1 was perform ed via South ern blot analysis. DN A was isolated from LCL according to standar d methods. DNA (5-10 fLg) was digested with EeoRI (Boeringe r Mannh eim, Indi anapolis, IN) or EeoRI + Eag I (New England Biolabs, Beverl y, MA), and subj ected to electroph oresis throu gh agarose until the 1-kb marker was at 14 ern. DNA was transferred to nylon membrane (Genescreen, DuP ont NEN, Boston, MA), and blots were probed with radiolabeled StB1 2.3, (14, 20) .e:
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RESULTS
This fragment is enlarged (5.3-5 .8 kb in premutation carriers and 6-12 kb in full mutation carriers) and contains the trinucleotide repeat expansion mutation in fragile X individuals. The enlarged segment of FMR-1 in individuals with a full mutation often appears as multiple bands or a smear due to presumed somatic instability of the amplified region (14, 15, 20) . Maximum, average, and minimum band or smear size for the mutated segment in DNA from fragile X LCL was determined by comparison with a 1-kb ladder and the norma15. EagI is 2.8 kb. Normal FMR-1 CGG repeat sizes in DNA from control LCL were measured via PCR followed by gel electrophoresis and autoradiography of radiolabeled PCR products, exactly as described by Levinson et al. (21) .
R T-PCR of FMR-I eDNA .
For RT-PCR (reverse transcription followed by PCR), total RNA was isolated from fresh pelleted cells according to the method of Chomczynski and Sacchi (22) . Total cellular RNA (5 p.,g) was subjected to RT-PCR according to the method of Pieretti et al. (15) . Primers specific for FMR-1 were 4687 and 4747 (15) from positions 989-1009 and 1112-1 134 of the FMR-1 cDNA sequence (12) . Primers used for hypoxanthine-guanine phosphoribosyl transferase cDNA were 243 and 244 (23) . PCR products were visualized on a 3% agarose gel stained with ethidium bromide.
Cyclic AMP production in fragile X and control LCL. cAMP production in control and fragile X LCL in the presence of various agents is compared with cAMP production in control and fragile X platelets (10) in Figure 1 . Defective cAMP production was more evident in fragile X platelets, with PGE 1 -and FSK-stimulated cAMP production 65% (p = 0.001) and 53 % (p = 0.001) of the control group, respectively. cAMP production in IBMX alone in fragile X platelets was 50% of control (p < 0.05) but not different in LCL. FSK-stimulated cAMP production in fragile X LCL was not significantly different from controls due to high variability in FSK responsiveness between individual cell lines and the relatively low levels of stimulation intrinsic to the tissue. Nonetheless, the same basic pattern of cAMP production in fragile X samples (with magnitude of averaged FSK-stimulated production values lower than averaged PGE1-stimulated produc tion values relative to averaged control data) was seen in both the platelet and LCL samples. Dose responses performed in a limited number of fragile X (n = 6) and control (n = 6) LCL indicated that, as in platelets (9, 10), reduced cAMP production was due to diminished maximum response rather than a shift in potency of reagents.
In a separate single assay (data not shown), LCL from cytogenetically positive fragile X female carriers with full mutations (n = 3) showed lower cAMP production than those from cytogenetically negative females with premutations (n = 3). This was not a statistically significant finding due to low sample number; however, again the magnitude of averaged FSK-stimulated cAMP production was the lowest comparative cAMP measure in the group of full mutation cells.
No relationship was seen between cAMP production and LCL growth rate, measured as f H]thymidine incorporation , in either fragile X or control cell groups or in the combined group. Passage number was also not correlated with cAMP production in any group. As seen in platelets (10), age and sex of the individu al from whom the LCL was derived had no effect on cAMP production in control LCL. 
DISCUSSION
We have described a pattern of diminished cAMP production in platelets (9, 10) and now LCL from fragile X patients. Molecular analysis of DNA from fragile X LCL has shown a correlation between measures of cAMP production not associated with receptor stimulation and the length of the fragile X amplification mutation in these lines. The pattern of decreased cAMP production with FSK-stimulated cAMP production being more affected than PGE1-stimulated production (particularly evident in platelets) suggests decreased activity of a catalytic subunit of adenylate cyclase rather than defective receptor coupling in fragile X tissues. The pattern of fragile X mutation amplified DNA segment length correlations supports this suggestion, with significant correlations with measures of cAMP production which reflect directly the activity of the catalytic subunit of adenylate cyclase and no correlation with PGE 1 (receptor)-mediated stimulation of cAMP production.
Of the eight known catalytic subunits of adenylate cyclase, at least types 6 and 7 are expressed in some lymphoid cells (LCL have not been specifically studied), whereas all eight are expressed in brain (24) . Platelets express high levels of FSKstimulable cyclase activity, and high affinity FSK binding sites which resemble those in brain and which appear to be related to presence of type 1 cyclase (25) , the species most prevalent in brain (26) . Platelets therefore represent a more accurate model for studies of regulation and FSK-stimulability of brain cyclases. Levels of stimulable cAMP production are much lower in LCL than platelets and make the cAMP production defect more difficult to demonstrate statistically in fragile X LCL relative to controls, despite a pattern of decreased prounmethylated premutation size band), none of the LCL subclones showed premutation or methylation mosaicism-all had completely methylated bands or smears, suggesting complete inactivation of the FMR-1 gene. In agreement with this finding, the RT-PCR assay for FMR-1 mRNA demonstrated normal hypoxanthine-guanin e phosphoribosyl transferase product but no FMR-1 product in all fragile X LCL, indicating complete lack of expression of FMR-1 mRNA in these lines. All control LCL expressed FMR-1 mRNA.
In control LCL, the size of the normal FMR-l repeat sequence (range 21-49 CGG repeats) determined by PCR did not correlate with any measure of cAMP production (basal, r = -0.09, p = 0.69; IBMX, r = -0.11, P = 0.64; PGE 1, r = -0.07, P = 0.75; FSK, r = -0.03, p = 0.89), suggesting the correlation with amplified CGG repeat size is specific to fragile X cell lines. The control CGG repeat range is small relative to the range (about 300-2300 repeats) of size variation in fragile X cells and CGG repeat variation in normal cells is not enough to allow visualization of size differences on Southern blots, on which all of the control EcoRI-digested DNA samples gave the expected 5.2-kb fragment.
There was no relationship between patient IQ and cAMP production, fragile site percentages, or size of amplified DNA segments in fragile X LCL (see Fig. 2 ). Somatic mosaicism in tissues from fragile X patients, however, would preclude any conclusions about these potential correlations in brain tissue. ..
Correlation of cAMP production with FMR-l amplification mutation in fra gile X LCL. All measurements of cAMP production in fragile X LCL (n = 19) except PGE1-stimulated cAMP production were inversely correlated with the maximum Correlations between cAMP production and average amplified DNA segment lengths are shown in Figure 2 . Minimum amplified DNA segment length did not correlate significantly with any measure of cAMP production. Fragile site percentages in fragile X LCL did not significantly correlate with maximum, average, or minimum amplified DNA segment lengths although there was a trend toward higher fragile site percentages in LCL with larger amplification mutations (for average amplified DNA segment length, r = 0.4 and p = 0.09). Although a few fragile X patients in this study demonstrated a methylation mosaic pattern in DNA from blood (with a minor duction which very closely resembles that in platelets. Further, this assay is expected to measure cAMP production by all cyclases expressed in a given tissue. If only some type(s) of cyclase s are affected, the magnitude and ease of demonstration of the cAMP production deficiency may vary between tissues dependi ng on levels of expression of the affected cyclase(s).
Certainly there are many clinic al features of patients with fragil e X syndrome which might be expected to go along with defective cAMP production. These include the cognitive profile, with particular deficits in short-term memor y and sequencing (27) , and behavioral problems involving difficulties with habituation and hypersensitivity to environmental stimuli (28) . Also , there is thought to be an increa sed incidence of obesity in the fragile X population (29) , and obesity has been shown to be associated with lower cellular accumul ation of cAMP (30) . Finally, patients with fragile X syndrome tend to exhibit overgrowth, especially early in life, of a number of body parts includin g ears and head size (31) . Later in life, testes are enlarged. Decreased intracellular cAMP levels might be associated with excess ive cellular proliferation due to enhancement of activity of the Ras/Raj cascade (32) .
No corre lation is seen between cAMP production and fragile site percentages when both are assayed in a single tissue at roughly the same time in culture and under highly standardized conditions. Although we previously reported a correlation betwe en fragile site percentage in lymphocytes and cAMP product ion in platelets from a small number of fragile X patients (10) , the prior lymphocyte data may have been influenced by dietary or patient factors . The LCL experiments are free of such variables, allow correlatio n of parameters in a single tissue and therefore are expected to give a more accurate result . It is still possible that higher cAMP production in platelets and lower fragile site percentages in lymphocytes from certain fragile X patients resulted from "methylation mosaicism" in these patients. None of the fragile X LCL examined was methylation mosaic , so this was not a confounding variable in this study.
There was also no significant correlation between length of the amplified DNA segment in the full mutation and percent of fragile sites in the LCL in this study. This is consistent with the correlation of cAMP measures with amplified segment length but not with percent fragile sites. Other investigators (33, 34) have published correlations between amplified segment length and percent fragile sites; however these studies include premutation carriers who have smaller mutations and lower or absent cytogen etic expression. Our data are in agreement with that from the large multic enter study of Rousseau et at. (35) which did not demonstrate a significant corre lation between percent fragile sites and mutation size when 224 male carriers of a full mutation were analyzed alone.
Recent studies suggest that the 4.8-kb FMR-l mRNA is alternatively spliced into at least 12 isoforms (36, 37) which are mainly identified in the cytoplasm (16) and bind RNA (38) , includin g about 4% of brain transcripts. Thus , the FMR-l protein family might theoretically serve to regulate gene products impo rtant in neural function through interacti on with specific RNAs. Alteration of such regulatory processes might lead to previously documented abnormalities of dendrit ic spine formation (39) and regional neuroanatomical abnormalities observed in fragile X brain (40) . The FMR-l protei n could regulate activity of one or severa l of the eight adenylate cyclases expressed in brain as well as other signal transduction systems through interaction with specific RNA. This hypothesis provides an attractive explanation for the finding of overall diminished cAMP production in severa l fragile X tissues but the effect of mutation size on cAMP producti on is difficult to explain on this basis, as all fragile X LCL appear to be equally and completely lacking in expression of the FMR-l protein. It is possible that small, although currently undetectable, amounts of FMR-l transcription may occur, with more transcription occurring in genes with smaller mutations. This wo uld presuppose exquisite sensitivity of cAMP production to very small amounts of FMR-l protein. Diminished cAMP production would be expected to be better correlated with the degree of methylation at the FMR-llocus than with size of the mutation. PGE 1 and FSK-stimulated cAMP production measured in an LCL from a single patient with an unmethylated full mutati on (and 50% normal FMR-l protein levels) was intermediate to averaged values from control and fragile X LCL analyzed in the same assay (41) . This result would tend to support the concept of a relationship between the FMR-l protein and cAMP production , but data from a series of such patients would be requir ed before a definitive conclu sion could be drawn.
Alternatively, increasing size of unstable DNA in the FMR-l amplificatio n mutation may be related to dimin ished cAMP production due to alteration of transcription of genes near FMR-l. Hansen et at. (42) have shown large var iable late replication domains at the FMR-l locus and extending at least 150-kb 5' and 34-k b 3' of the expanded CGG repeat, implying that genes in addition to FMR-l may be affected. It appears, however, that abnormal FMR-l function is suffi cient to produce the phenotype, as a severely affected patient with a point mutation affecting one of the RNA binding domains has been described (43) . PGE \ and FSK-stimulated cAMP production in an LCL from this patient was intermediate to values from control and fragile X samples in a single assay. These data do not definitively support either of the above hypotheses and is difficult to interpret on the basis of only one cell line with an FMR-l point mutation. Again, a series of such lines would be needed.
Further studies with tissues from fragile X patients with varying abnormal replication domain size at FMR-l, with fully or partially unmethylated full mutations and with FMR-l gene abnormalities other than the CGG repeat amplification mutation may help distinguish between a direct effect of FMR-l on cAMP cascade function versus diminished cAMP production due to alteration of transcription of a closely linked gene. In either case abnormal cAMP cascade function may contribute to cognitive dysfunction in patients with fragile X syndrome.
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